Xenetic Biosciences Inc. recently moved its operations from London to the United States and held a grand opening for its new corporate headquarters and research and development facility in Lexington.

The 3,500-square-foot headquarters is located at 99 Hayden Road. Xenetic Biosciences Inc. is a biopharmaceutical company that focuses on developing next-generation biologic drugs and novel oncology.

"The opening of Xenetic’s new corporate headquarters in Lexington marks an important new phase in the company’s 17-year history. Moving our development operations to the Massachusetts biotech corridor is an important step in our transition to becoming an innovative biopharmaceutical company based and publicly listed in the U.S.," Scott Maguire, CEO of Xenetic, said in a statement. "We believe that we are much more strongly positioned to execute on our mission to develop and commercialize leading next-generation biologic drugs and novel oncology therapeutics."

Massachusetts Life Sciences Center (MLSC) and the Massachusetts Biotechnology Council co-hosted the Hayden Road facility’s ribbon-cutting ceremony.

"On behalf of the center, I would like to welcome Xenetic to Massachusetts," MLSC President and CEO Susan Windham-Bannister said in a statement. "Xenetic is focused on developing a pipeline of therapeutics for the treatment of rare diseases, and Massachusetts is the perfect home for the company’s cutting-edge technology."